Condition Focus: Macrophage Polarization — Wavelength and Timing Specificity

If wavelength determines which pathway PBM activates, does it also determine when those effects peak? This in vitro study from Fernandes and colleagues directly compared two wavelengths — 660 nm (visible red) and 780 nm (near-infrared) — for their effects on macrophage inflammatory mediator expression at different time points after treatment.

Using LPS and IFN-γ to drive M1 polarization (pro-inflammatory) and IL-4 for M2 polarization (anti-inflammatory), the researchers measured chemokine and cytokine expression at multiple post-treatment intervals. The key finding: 660 nm PBM reduced CCL3, CXCL2, and TNF-α expression in M1 macrophages at the 4-hour mark, while 780 nm showed differential timing effects. This suggests that different wavelengths do not simply do “more” or “less” of the same thing — they modulate macrophage behaviour through different temporal patterns.

For device design, this means that combining wavelengths is not redundant — it may achieve a broader temporal window of anti-inflammatory effects. A dual-wavelength device could potentially provide both rapid early suppression of M1 markers (via the red component) and sustained or complementary effects (via the NIR component).

The 660 nm findings are directly relevant to the G.O.A.T. because they demonstrate that the visible red wavelength has specific, measurable anti-inflammatory effects on macrophage polarization that are distinct from NIR effects — confirming that the shorter wavelength in a dual-wavelength device is doing meaningful anti-inflammatory work, not just providing surface-level effects.

G.O.A.T. for Gout Alignment:
The G.O.A.T.’s 660 nm wavelength is identical to the red wavelength studied here. The rapid (4-hour) M1 suppression at 660 nm supports the G.O.A.T.’s rationale for including this wavelength alongside 850 nm: the red component addresses macrophage inflammation in the acute phase while the NIR component provides deeper tissue and potentially extended temporal effects.

Link to original research here

Editor’s note: The wavelength-specific timing demonstrated here adds granularity to the comprehensive M1→M2 review in M1→M2 Polarization Review 2025. The PI3K/AKT/mTOR pathway that may underlie the timing differences is mapped in Tian et al 2023. For the COX-2/PGE₂ pathway effects of 660 nm in joint tissue, see Albertini et al 2007. The 660 nm edema reduction via cannabinoid receptors is explored in Neves et al 2018.

Related Articles

• PBM and Macrophage Polarization: M1→M2 Shift Review – 2025
• PBM Increases M2 Macrophages via PI3K/AKT/mTOR at 980nm – Tian et al 2023
• Anti-Inflammatory Effect of PBM on COX-2 and PGE₂ in Joint Inflammation – Albertini et al 2007
• PBM Improves Acute Inflammation via Cannabinoid Receptor Activation – Neves et al 2018
• PBM Modulates Macrophage via Notch1-HIF-1α-NF-κB: RNA-seq – Ma et al 2022

Key Takeaways

• 660 nm reduces M1 inflammatory markers (CCL3, CXCL2, TNF-α) at 4 hours post-treatment
• 780 nm shows different temporal effects — wavelengths operate on different schedules
• Dual-wavelength devices may achieve broader temporal anti-inflammatory coverage
• Confirms 660 nm has specific, measurable anti-inflammatory effects on macrophages

Study Overview

Full Citation

Fernandes KP, et al. (2019). Differential expression of inflammatory mediators by M1 and M2 macrophages after photobiomodulation with red or infrared lasers. Lasers in Medical Science, 34(7), 1467–1477. View Publication